万方数据万方数据万方数据万方数据乳腺癌患者HER2基因检测——带着问题重读《ASCO/CAP指南》作者：王炜， 项晶晶， 崔海东， 刘坚， 徐如君作者单位：王炜,项晶晶,徐如君(310006,杭州市第一人民医院病理科)， 崔海东,刘坚(310006,杭州市第一人民医院乳腺外科)刊名：中华外科杂志英文刊名：Chinese Journal of Surgery年，卷(期)：2013,51(10)1.Wolff AC.Hammond ME.Schwartz JN American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer 20072.Perez EA.Dueck AC.McCullough AE Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria 20123.Perez EA.Reinholz MM.Hillman DW HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial 20104.Starczynski J.Atkey N.Connelly Y HER2 gene amplification in breast cancer:a rogues' gallery of challenging diagnostic cases:UKNEQAS interpretation guidelines and research recommendations 20125.Petroni S.Addati T.Mattioli E Centromere 17 copy number alteration:negative prognostic factor in invasive breast cancer 20126.Perez EA.Press MF.Dueck AC Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 inclinical trials of adjuvant therapy for breast cancer (NCCTG N9831,BCIRG 006,and BCIRG 005) 20137.Valent A.Penault-Llorca F.Cayre A Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer:polyploidization can lead to diagnostic pitfalls with potential impact for clinical management 20138.Tse CH.Hwang HC.Goldstein LC Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes:implications for antiHER2 targeted therapy 20119.Gunn S.Yeh IT.Lytvak I Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity 201010.Ross JS Human epidermal growth factor receptor 2 testing in 2010:does chromosome 17 centromere copy number make any difference 201011.Pritchard KI.Munro A.O'Malley FP Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response:evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial 201212.Vance GH.Barry TS.Bloom KJ Genetic heterogeneity in HER2 testing in breast cancer:panel summary and guidelines 200913.Bartlett AI.Starcyznski J.Robson T Heterogeneous HER2 gene amplification:impact on patient outcome and a clinically relevant definition 201114.Allison KH.Dintzis SM.Schmidt RA Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations:time for a new look at how to report heterogeneity 201115.Chang MC.Malowany JI.Mazurkiewicz J" Genetic heterogeneity" in HER2/neu testing by fluorescence in situ hybridization:a study of 2522 cases 201216.Brunelli M.Manfrin E.Martignoni G Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification:evaluation according to ASCO/CAP criteria 200917.Press MF.Finn RS.Cameron D HER-2 gene amplification,HER-2 and epidermal growth factor receptor mRNA and protein expression,and lapatinib efficacy in women with metastatic breast cancer 200818.Yang YL.Fan ng RG Genetic heterogeneity of HER2 in breast cancer:impact on HER2 testing and its clinicopathologic significance 201219.Nakamura R.Yamamoto N.Onai Y Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients[published online ahead of print February 25,2012] 201220.Houssami N.Macaskill P.Balleine RL HER2 discordance between primary breast cancer and its paired metastasis:tumor biology or test artefact? Insights through meta-analysis 201121.Li P.Liu T.Wang Y Influence of neoadjuvant chemotherapy on HER.2/neu status in invasive breast cancer 201322.Paik S.Kim C.Wolmark N HER2 status and benefit from adjuvant trastuzumab in breast cancer 200823.Clay MR.Iberri DJ.Bangs CD Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution 201324.Park S.Park HS.Koo JS Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization 201225.Sauter G.Lee J.Bartlett JM Guidelines for human epidermal growth factor receptor 2 testing:biologic and methodologic considerations 2009本文链接：/Periodical_zhwk201310003.aspx。